Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 7, 2015; 21(13): 3904-3911
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3904
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3904
Figure 1 Study flow chart.
PEG-IFNα: Pegylated interferon-α; HCV: Hepatitis C virus; SNP: Single nucleotide polymorphism.
Figure 2 Sustained virologic response rates according to interferon-λ3 single nucleotide polymorphism genotype.
A: Rapid virologic response (RVR); and B: Non-RVR patient groups. SVR: Sustained virologic response; SNP: Single nucleotide polymorphism; IFNL3: Interferon-λ3.
Figure 3 Sustained virologic response rates according to interferon-λ3 single nucleotide polymorphism genotype and hepatitis C virus sub-genotype.
A: Rapid virologic response (RVR); and B: Non-RVR patient groups. HCV: Hepatitis C virus; RVR: Rapid virologic response; SNP: Single nucleotide polymorphism; IFNL3: Interferon-λ3.
- Citation: Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C. World J Gastroenterol 2015; 21(13): 3904-3911
- URL: https://www.wjgnet.com/1007-9327/full/v21/i13/3904.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i13.3904